RNS Announcements

Unaudited Interim Results to 30 June 2025

08 September 2025

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces its unaudited results for the six months to 30 June 2025.

Download

To view a full version of the results in 
PDF format  click here

Key Financial Highlights

  • Gross revenue +33% to £1.34m (H1 2024: £1.01m)
  • Gross profit +33% to £748,000 (H1 2024: £564,000)
  • EBITDA loss (excluding share-based payments) reduced by 52% to £112,000 (H1 2024: £232,000 loss)
  • Growth in all markets with sales outside USA +127% to £584,000 (H1 2024: £257,000)
  • Strong cash balance of £1.3m (H1 2024: £865,000)
  • Current trading robust with order book at a record level

Operational Highlights

  • A number of new commercial partnerships secured across Europe, the US and Asia Pacific
  • Appointment of new sales executive in the US expected to drive further growth in North America
  • First commercial manufacturing of LPLDL completed through our CMO partnership in Canada
  • Launch of two new menopause-focused women’s health concepts – YourBiotix MH and YourBiotix PMH
  • Initiated discussions with the Steno Research Foundation in Denmark, to explore a clinical study investigating the potential effects of LPLDL in individuals with diabetes

    •  

    Steen Andersen, CEO of ProBiotix, commented: “We are pleased with the progress that has been achieved in the first half of 2025, which has resulted in another record performance. The increasing consumer awareness and market focus on preventive cardiometabolic supplement products continues to expand at an impressive pace (CAGR over the next 5-year period >8%), reflecting the growing demand for effective, science-backed health solutions.

    “The successful product launches by our partners achieved over the past few years, and the accelerating consumer acceptance, confirms our belief in the tremendous long-term potential for the Company. We remain committed to executing the growth strategy to deliver sustainable value for shareholders, and look forward to reporting further on our progress.”

    For further information, please contact:

     

    ProBiotix Health plc https://probiotixhealth-ir.com/
    [email protected]
    Steen Andersen, Chief Executive Officer
    Miles Nolan, Investor Relations
      
    Peterhouse Capital Limited
    Aquis Corporate Adviser and Broker     		 
     
     
    Mark Anwyl
    Duncan Vasey
          		Tel: 020 7469 0930

    This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

    Notes to Editors:

    ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.

    The Company has a singular approach: discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.

    back to RNS & Investor News